Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Doses First Patient in China Trial of "Don't Eat Me" Inhibitor

publication date: Jan 15, 2019

Suzhou Innovent Biologics has dosed the first patient in a China Phase I clinical trial of its anti-CD47 mAb (IBI188), an inhibitor of the "Don't Eat Me" pathway. By binding CD47, IBI188 is expected to promote the phagocytosis of tumor cells by macrophages. Innovent plans to conduct several clinical trials to assess the efficacy of IBI188 in multiple tumor types, including non-Hodgkin's lymphoma and ovarian cancer. Innovent emphasized that IBI188 has a different mechanism that the check point inhibitors PD-1, PD-L1 and CTLA-4. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.